Navigation Links
Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain
Date:11/28/2008

INDIANAPOLIS, Nov. 28 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) has withdrawn its supplemental New Drug Application (sNDA) from the U.S. Food and Drug Administration (FDA) for Cymbalta(R) (duloxetine HCl) for the management of chronic pain. Lilly plans to resubmit the application in the first half of 2009, adding data from a recently completed positive study in chronic osteoarthritis pain of the knee.

The decision does not affect duloxetine's FDA-approved indications for major depressive disorder, generalized anxiety disorder, management of diabetic peripheral neuropathic pain and management of fibromyalgia.

Lilly submitted the chronic pain application in the second quarter of 2008 based primarily on outcomes of three clinical trials: one positive study in chronic osteoarthritis pain of the knee(i) and two studies(ii,iii), -- one positive and one that is supportive but didn't meet its primary endpoint -- in chronic low back pain. In discussions between Lilly and the FDA, agency reviewers raised questions about efficacy and dosing that revolved primarily around statistical methodology and study design.

"This was a difficult decision, but we believe the updated data package will give the FDA a broader basis for reviewing our application," said John Hayes, M.D., a Lilly Research Laboratories vice president at Lilly.

Chronic pain affects more than 50 million Americans(iv) and pain is a major cause of work absenteeism, underemployment and unemployment.(v,vi,vii,viii)

About Duloxetine

Serotonin and norepinephrine in the brain and spinal cord are believed to both mediate core mood symptoms and help regulate the perception of pain. Based on preclinical studies, Duloxetine is a balanced and potent reuptake inhibitor of serotonin and norepinephrine that is bel
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application
2. Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement
3. Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimers Disease Compound
4. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
5. Phase II Data on Lillys Antibody Show It Affects Amyloid Beta, a Protein Believed To Be Associated with Alzheimers Disease
6. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
7. Lilly and TransPharma Medical Announce Licensing and Development Agreement
8. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
9. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
10. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
11. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... -- About Chronic Lymphocytic Leukemia Chronic ... production of lymphocytes. It has been observed that the ... to other parts of the body. This leukemia is ... buildup of the cancerous cells. During the course of ... and lymph nodes. The course of the disease is ...
(Date:9/2/2015)... DUBLIN , Sept. 2, 2015 Research and ... "Pharmaceutical Regulatory Affairs in China (Basel, Switzerland - November ... This seminar will provide a detailed overview of the key ... , Hong Kong , Macau ... cover: - All important aspects of gaining ...
(Date:9/2/2015)... Coast Tattoo Removal is the first and only laser clinic ... Southern Mississippi . Gulf Coast Tattoo Removal helps ... control of their skin. The clinic is located in ... Biloxi , Gulfport , and the entire ... as it is, I was surprised by the lack of laser ...
Breaking Medicine Technology:Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 2Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 3Pharmaceutical Regulatory Affairs in China Seminar: Basel, Switzerland - November 26-27, 2015 2Gulf Coast Tattoo Removal Delivers Unrivaled Tattoo Removal Results To Biloxi And Gulfport With Astanza Duality 2
... LAKE ZURICH, Ill., Dec. 15 Fenwal Inc., a global ... and availability, announced today that the U.S. Food and Drug ... platelet additive solution. Fenwal ® InterSol ® ... plasma to store donated platelets, a vital blood component used ...
... , , NEW ... market research report is available in its catalogue: , ... Market Forecasts to 2015 , http://www.reportlinker.com/p0167308/Systemic-Lupus-Erythematosus---Drug-Pipeline-Analysis-and-Market-Forecasts-to-2015.html ... and Market Forecasts to 2015 , Summary ...
Cached Medicine Technology:Fenwal Receives FDA Approval for New Solution Used to Store Donated Blood Platelets 2Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 2Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 3Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 4Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 5Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 6Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 7Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 8
(Date:9/2/2015)... ... September 02, 2015 , ... According to an article published August 12 by International ... aims to do away with grand juries in cases meant to decide if a police ... response to grand jury decisions in Ferguson and New York City that absolved police officers ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... – in the news recently following a decision by the Centers for Medicare ... is likely to average approximately $71,000 or roughly 40% of its headline-grabbing $178,000 ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... announced today the launch of its enhanced, cloud-based mobile ePrescribing application. The release ... focus on improving prescriber usability. A leader in health technology, RxNT was one ...
(Date:9/2/2015)... , ... September 02, 2015 , ... ... incoming goods, intermediate or final products. Automating sample handling makes density measurements more ... handling, showing each step of the automated workflow and the advantages compared to ...
(Date:9/2/2015)... ... September 02, 2015 , ... A UPMC and ... earned international recognition as a premier center for treatment of and research into ... internal bleeding and stroke. , Cure HHT, previously known as The HHT ...
Breaking Medicine News(10 mins):Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 2Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 2Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 4Health News:RxNT Releases Enhanced ePrescribing iPhone App to Improve Prescriber Usability 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 3Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 2Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 3Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 4
... on the development and commercialization of proprietary pharmaceuticals ... partners , today announced that under the Special ... with the United States Food and Drug Administration ... protocol for crofelemer for the treatment of chronic ...
... Functional foods could be the rage today in advanced ... better ask some tough questions before they decide ... ,Currently the international functional foods market is a ... ,* Margarines that lower bad cholesterol (LDL). ...
... at the University of Southern California have applied a ... clear up an old puzzle of the global carbon ... an advanced online publication of The ISME Journal. ... for nanometer-scale, secondary ion mass spectrometry) located at Lawrence ...
... to get hookah smoking exempted from Englands smoking ban ... the health effects , doctors writing in this weeks ... ,A hookah is a glass based waterpipe used ... for smoking herbal fruits after meals, but it is ...
... disease gives a more accurate measure of how many UK ... adults are most likely to benefit from treatment . ... the general population without pre-existing cardiovascular disease or diabetes, there ... Britain at high risk of developing heart disease. This is ...
... and Children's Hospital, Adelaide in Australia has raised serious questions ... are exposed to every day. ,Titled The ... ageing facilities in two of the hospital's oldest buildings and ... ,It states: "WCH is experiencing immediate facilities, infrastructure and related ...
Cached Medicine News:Health News:Napo Obtains Special Protocol Assessment Agreement From FDA for Crofelemer 2Health News:Functional Food What is That, Ask First 2Health News:Functional Food What is That, Ask First 3Health News:Nanospectrometer Aids in Identifying Nutrient Cycle 2Health News:Ban on Hookah Smoking Should Stay, Argue Doctors 2Health News:New Heart Disease Risk Score Will Help Minimise Health Inequalities 2Health News:New Heart Disease Risk Score Will Help Minimise Health Inequalities 3Health News:Concerns Raised Over Risks for Patients and Staff in Australian Hospital 2
New system has all of the features of the EPT-1000TC. Now with 100 watts RF power using the Blazer II XP catheter....
6.5mm diameter handpiece; 75mm handle with grooves for grip; Standard male luer taper fits most cannula hub and female luer taper....
45 degree angled; 5mm from bend to tip; overall length excluding hub 16mm; In Stainless Steel...
3 Piece with .35mm Angled Point, Curved to Left, #8, Side Opening Irrigation, 40mm overall length; in stainless steel; 30cm Long Silicone Tubing with Connector....
Medicine Products: